Symbol
| TRPC3
| contributors: mct/pgu - updated : 28-08-2020
|
HGNC name
| transient receptor potential cation channel, subfamily C, member 3
|
HGNC id
| 12335
|
corresponding disease(s)
|
SCA41
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
constitutional
|  
|  
| --over
|  
|
enhanced expression in type 2 diabete mellitus patients | constitutional
|  
|  
|  
| loss of function
|
TRPC3 deficiency inhibited high salt-induced cardiac hypertrophy | |
Variant & Polymorphism
|
| |
Candidate gene
| as an emerging candidate protein implicated in various forms of ataxia in humans |
Marker
Therapy target
|
System | Type | Disorder | Pubmed |
cardiovascular | aquired | heart failure | |
pharmacologic inhibitors of TRPC channels might be a strategy for attenuating local Ca2+ signals involved in pathologic cardiac hypertrophy or failure | cardiovascular | rythm | | |
TRPC3 represents a promising target to prevent conduction disturbances | cardiovascular | aquired | heart failure | |
may represent a novel target for preventing high salt-induced cardiac damage | miscelleaneous | urinary | | |
TRPC3 might be a promising target for autosomal dominant polycystic kidney disease (ADPKD) treatment |
| | |
| gain-of-function mutation (T635A) in the transient receptor potential (TRP) channel Trpc3 results in abnormal channel gating and causes cerebellar ataxia in the dominant Moonwalker (Mwk) mouse mutant ( | |
double Trpc3/Trpc6 knock-out mice showed hearing impairment, vestibular deficits and defective auditory brain stem responses to high-frequency sounds |